Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2014 | ASH 2014: Phase II SPRINT study of lenalidomide in relapsed/refractory mantle cell lymphoma

Marek Trněný • 5 Dec 2015
ASH 2014
Mantle Cell Lymphoma Lenalidomide
SPRINT

Prof Marek Trněný (Charles University Hospital, Prague, Czech Republic) at the 2014 American Society of Hematology (ASH) Annual Meeting discusses the phase 2 SPRINT (MCL-002) study of lenalidomide versus investigator’s choice in relapsed or refractory mantle cell lymphoma, including the study design, efficacy and safety endpoints, and conclusions

More from Marek Trněný

Evolving treatment landscape of MCL
John Kuruvilla et al. • 17 Oct 2023
2:28
Improving outcomes for R/R DLBCL with polatuzumab vedotin
Marek Trněný • 14 Jun 2018
1:59
Rituximab maintenance key to outcome improvement in mantle cell lymphoma
Marek Trněný • 14 Jun 2018
3:12
Prognostic indices for follicular lymphoma: PRIMA-PI
Marek Trněný • 14 Jun 2018

Related Videos

3:32
BGB-16673, a novel BTK degrader, in patients with R/R B-cell malignancies
John Seymour • 8 Dec 2023
2:25
The future of CAR-T for the treatment of lymphoma
Anna Sureda • 7 Mar 2024
2:40
The impact of CAR-T on the role of SCT in lymphoma
Anna Sureda • 7 Mar 2024
0:44
A case report of CAR-T-related neurotoxicity presenting as delayed aseptic meningitis in MCL
Stefania Bramanti • 17 Feb 2024
The content of VJHemOnc is intended for healthcare professionals